For people living with diabetes, keeping glucose levels in check is a daily priority. Wearable glucose monitors have transformed how that task gets done—and understanding how Medicare covers these devices can make a real difference in access and affordability.
What Is a Wearable Glucose Monitor?
A continuous glucose monitor, commonly called a CGM, is a small medical device worn on the body that tracks blood sugar levels around the clock. Rather than requiring a traditional fingerstick to draw blood, the device attaches to the skin—typically on the stomach or arm—and uses a tiny plastic tube to read glucose from the fluid just beneath the skin’s surface (source).
Inside the device, a miniature sensor estimates glucose levels every few minutes and continuously records those readings over time (source). This real-time data stream gives both patients and their healthcare providers a far more detailed picture of glucose patterns than a single fingerstick reading ever could. Trends, spikes, and drops become visible across hours and days, enabling smarter, faster decisions about food, activity, medication, and lifestyle.
How CGM Devices Work and How Long They Last
Most CGM sensors are disposable and need to be swapped out every seven to fourteen days, depending on the specific model being used (source). Rotating the placement site each time a new sensor is applied helps prevent skin irritation from developing over time (source). There are also implantable CGM sensors available that can remain in place significantly longer—some lasting up to 180 days before replacement is needed (source).
Doctors can prescribe these devices for both adults and children, with certain models approved for use in children as young as two years old (source). The breadth of available options means that the right device can often be matched to an individual’s age, lifestyle, and medical needs.
The Benefits of Continuous Glucose Monitoring
Compared to standard blood glucose meters, CGMs offer a number of meaningful advantages. Users can better manage their day-to-day glucose levels, experience fewer dangerous episodes of low blood sugar, and reduce the number of finger-stick tests they need to perform (source).
One particularly useful metric that CGMs make possible is called “time in range,” or TIR. This measurement reflects the percentage of each day that a person’s glucose stays within a healthy target zone. For most individuals, that target sits between 70 and 180 mg/dL, and the general goal is to remain within that range for at least 70 percent of the day—roughly 17 hours out of every 24 (source). Having this kind of ongoing feedback empowers people with diabetes to make timely adjustments rather than reacting only after levels have already gone off track.
Medicare Coverage for Wearable Glucose Monitors
Medicare covers CGM devices under Part B as durable medical equipment (DME), which means certain eligibility requirements must be met before coverage kicks in (source). To qualify, a person must have diabetes and either take insulin or have a documented history of hypoglycemia-related problems. Additionally, the individual or their caregiver must have received sufficient training to operate the device properly (source).
The ordering process also has specific requirements. A doctor or other qualified healthcare provider must evaluate the patient first to confirm eligibility before placing an order for the equipment (source). It is important that both the prescribing provider and the DME supplier are enrolled in Medicare, as this affects whether the claim will be processed and covered.
On the cost side, once a Medicare beneficiary has met the Part B deductible, they are generally responsible for 20 percent of the Medicare-approved amount when the supplier accepts assignment (source). For many people, this represents a significant reduction compared to paying out of pocket for both the device and its ongoing supplies, such as replacement sensors.
Private insurance plans and Medicaid also commonly extend coverage to CGM devices. People with type 1 diabetes often qualify with minimal monthly costs, and those with type 2 diabetes who use insulin injections, an insulin pump, or who have experienced severe low blood sugar episodes are typically covered as well (source). This broad coverage landscape reflects the growing recognition that continuous glucose monitoring is a clinically valuable tool, not simply a convenience.
Who Should Talk to Their Doctor About a CGM?
Anyone managing diabetes who wants a more complete view of their glucose patterns may benefit from asking their healthcare provider about continuous glucose monitoring. The conversation is especially relevant for those who already use insulin, have experienced unexpected blood sugar crashes, or find it difficult to maintain stable glucose control using traditional monitoring methods alone. Since Medicare and most insurance plans require a provider evaluation and prescription before coverage applies, that conversation with a doctor is also the first practical step toward accessing the device.
Why You Should Learn More About Wearable Glucose Monitors and Medicare Today
Wearable glucose monitors represent a meaningful advancement in diabetes management, offering real-time data, reduced reliance on fingersticks, and sharper insight into daily glucose patterns. Medicare Part B covers these devices as durable medical equipment for eligible beneficiaries, making them more financially accessible than many people realize. Understanding the eligibility criteria—including the role of a qualified provider evaluation and properly enrolled suppliers—is essential for anyone considering this technology. Whether someone has type 1 or type 2 diabetes, speaking with a healthcare provider about CGM options and coverage is a practical, informed step toward better day-to-day health management.